Correlation Between Cadrenal Therapeutics and SAB Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cadrenal Therapeutics Common and SAB Biotherapeutics, you can compare the effects of market volatilities on Cadrenal Therapeutics and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics and SAB Biotherapeutics.

Diversification Opportunities for Cadrenal Therapeutics and SAB Biotherapeutics

0.7

Correlation Coefficient

Cadrenal Therapeutics  SAB Biotherapeutics

Poor diversification

The 3 months correlation between Cadrenal and SAB is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics Common and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Cadrenal Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics Common are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Cadrenal Therapeutics i.e., Cadrenal Therapeutics and SAB Biotherapeutics go up and down completely randomly.

Pair Corralation between Cadrenal Therapeutics and SAB Biotherapeutics

Given the investment horizon of 90 days Cadrenal Therapeutics Common is expected to under-perform the SAB Biotherapeutics. In addition to that, Cadrenal Therapeutics is 1.74 times more volatile than SAB Biotherapeutics. It trades about -0.11 of its total potential returns per unit of risk. SAB Biotherapeutics is currently generating about -0.11 per unit of volatility. If you would invest  446.00  in SAB Biotherapeutics on February 3, 2024 and sell it today you would lose (42.90) from holding SAB Biotherapeutics or give up 9.62% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	95.65%
Values	Daily Returns

Cadrenal Therapeutics Common  vs.  SAB Biotherapeutics

Cadrenal Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cadrenal Therapeutics Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's forward-looking signals remain rather sound which may send shares a bit higher in June 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

SAB Biotherapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days SAB Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in June 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Cadrenal Therapeutics and SAB Biotherapeutics

The main advantage of trading using opposite Cadrenal Therapeutics and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.

The idea behind Cadrenal Therapeutics Common and SAB Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.